Atypical mesothelial proliferation is the term a pathologist uses when mesothelial cells look abnormal but cannot be confidently called either reactive (benign) or malignant mesothelioma. It is a description of uncertainty, not a cancer diagnosis, and it usually leads to more testing, more tissue or close follow-up.
Origin
Pathologists have long struggled to tell reactive mesothelial cells, which can look alarming in inflamed pleura, from early mesothelioma. Expert guidelines from mesothelioma pathology panels encourage the term atypical mesothelial proliferation when the evidence falls short, rather than forcing a benign or malignant call.
Significance in Asbestos Context
The key sign of malignant mesothelioma is invasion of tumor cells into tissue beneath the lining, and small biopsies or fluid samples often cannot show it. Tests that help include immunostains for BAP1 and MTAP, where loss of the protein in the cells favors mesothelioma, and FISH for deletion of the CDKN2A gene. When these are inconclusive, doctors may recommend a larger thoracoscopic biopsy or repeat imaging and sampling. For a claim, an atypical proliferation is not a mesothelioma diagnosis, and trusts and courts will not accept it as one. It is, however, an important record: if mesothelioma is later confirmed, the earlier report helps date when the disease began. Patients in this situation benefit from review by a pathologist experienced in mesothelioma.
Example Sentence
The fluid cytology showed an atypical mesothelial proliferation, so the surgeon took thoracoscopic biopsies, which showed invasive epithelioid mesothelioma.
Related Terms
Reactive Mesothelial Hyperplasia, Reactive Mesothelial Cells, Mesothelioma in Situ, BAP1, MTAP, CDKN2A, Thoracoscopic Biopsy, Pathology Review
Notes
- Ask whether BAP1 and MTAP stains or CDKN2A testing were done on your sample.
- Ask whether a larger biopsy is possible and what the follow-up plan is.
- Keep every pathology report, even inconclusive ones; they can matter later.
- A second opinion from a mesothelioma pathologist is reasonable when the diagnosis is uncertain.
In the research library
25 studies in our medical research library mention Atypical Mesothelial Proliferation in the title or abstract. Among the most cited:
- Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targetsE.G. Ramírez-Salazar, L.C. Salinas-Silva, M.E. Vázquez-Manríquez, et al, 2014 · Experimental and Molecular Pathology · cited 31 times
- Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant MesotheliomaR. Pillappa, J.J. Maleszewski, W.R. Sukov, et al, 2018 · The American Journal of Surgical Pathology · cited 28 times
- Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasiaJ. Scurry, M.A. Duggan, 1999 · Journal of Clinical Pathology · cited 11 times
- Dose-dependent mesothelioma induction by intraperitoneal administration of multi-wall carbon nanotubes in p53 heterozygous miceA. Takagi, A. Hirose, M. Futakuchi, et al, 2012 · Cancer Science · cited 131 times
- Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology SpecimensH.C. Hwang, B.S. Sheffield, S. Rodriguez, et al, 2016 · The American Journal of Surgical Pathology · cited 125 times
The journals that publish most on it: The American Journal of Surgical Pathology (4), Pathology (2), Diagnostic Cytopathology (2).
Category: Diagnostic Tools & Biomarkers · All Lexicon terms A–Z
This page is provided for general informational purposes and does not constitute legal advice. Every asbestos case turns on its own facts, exposure history, diagnosis, deadlines, available evidence, and applicable law. Reviewing this page does not create an attorney-client relationship. For advice about your specific situation, call 833-4-ASBESTOS for a free case review.